new glp 1 agonist novo nordisk said on Tuesday its triple UBT251 of the receptors for GLP-1, GIP and glucagon, jointly developed with United Biotechnology, achieved a statistically significant mean weight loss of up to Novo inks Ascendis deal to
Description
GLP-1 RAs ameliorate hepatic steatosis through improved insulin sensitivity, direct suppression of hepatic de novo lipogenesis through AMPK activation and SREBP-1c inhibition, and enhanced fatty acid oxidation through PPAR upregulation
doi: 10.3390/ijms22147475 78 van OostveenWMde LangeECM
Rachele, Restores Chief Science Officer, adds
The mechanism of action of semaglutide involves binding to GLP-1 receptors in multiple tissues throughout the body
Preliminary studies indicate no significant negative impact on growth hormones, but more research is needed
A recent trial showed that even moderate protein insufficiency during GLP-1 use correlated with sarcopenia markers
